Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has announced the issuance of several patents. The claims of these patents cover novel immune modulatory oligonucleotides and their chemical modifications, each of which provide unique immune responses.
Subscribe to our email newsletter
Presently, the company holds over 220 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLRs 7, 8 and 9.
Steven Ritter, vice president of intellectual property and contracts of Idera, said: “The claims of these issued patents provide additional coverage for our expanding portfolio of synthetic DNA-based Toll-like Receptor (TLR)-targeted compounds. Our TLR-targeted compounds, agonists and antagonists, are designed using our chemistry-based approach.”